-
1 Comment
Living Cell Technologies Limited is currently in a long term uptrend where the price is trading 3.9% above its 200 day moving average.
From a valuation standpoint, the stock is 1371.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3788.0.
Living Cell Technologies Limited's total revenue sank by 55.6% to $120K since the same quarter in the previous year.
Its net income has dropped by 184.7% to $-643K since the same quarter in the previous year.
Finally, its free cash flow grew by 74.6% to $-313K since the same quarter in the previous year.
Based on the above factors, Living Cell Technologies Limited gets an overall score of 2/5.
| Exchange | AU |
|---|---|
| CurrencyCode | AUD |
| ISIN | None |
| Sector | None |
| Industry | None |
| Market Cap | None |
|---|---|
| PE Ratio | nan |
| Target Price | nan |
| Beta | nan |
| Dividend Yield | nan% |
None
Here's how to backtest a trading strategy or backtest a portfolio for LCT.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
